Update shared on17 Oct 2025
Fair value Increased 4.08%Narrative Update: Sotera Health Analyst Price Target Adjustment
Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.
What's in the News
- Sotera Health completed a Follow-on Equity Offering, raising $307 million by offering 20,000,000 shares of common stock at $15.35 per share (Key Developments).
- The company filed another Follow-on Equity Offering for $323.2 million, with 20,000,000 shares of common stock at a price of $16.16 (Key Developments).
- Sotera Health's executive officers, directors, and selling stockholders entered into lock-up agreements restricting sales of certain Common Stock, RSU, PSU, and Options from September 3 to October 19, 2025 (Key Developments).
- Sotera Health raised its 2025 full-year earnings guidance, increasing the projected net revenues growth range to 4.5% to 6.0% (Key Developments).
Valuation Changes
- Fair Value has risen slightly, moving from $16.33 to $17.00 per share.
- Discount Rate increased marginally from 8.31% to 8.31%.
- Revenue Growth remains essentially unchanged and steady at approximately 6.39%.
- Net Profit Margin is stable and unchanged at around 23.20%.
- Future P/E ratio has increased modestly from 18.89x to 19.66x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.